AngioDynamics Inc. (NASDAQ:ANGO) updated its FY17 earnings guidance on Wednesday. The company provided EPS guidance of $0.62-0.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.63. The company issued revenue guidance of $355-360 million, compared to the consensus revenue estimate of $359.18 million.
Several research analysts recently issued reports on the company. Zacks Investment Research raised AngioDynamics from a hold rating to a buy rating and set a $18.00 target price on the stock in a research report on Wednesday, September 14th. KeyCorp set a $18.00 target price on AngioDynamics and gave the company a buy rating in a research report on Monday, September 12th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. AngioDynamics currently has a consensus rating of Hold and an average target price of $15.20.
AngioDynamics Inc. (NASDAQ:ANGO) opened at 16.47 on Thursday. The stock has a 50 day moving average price of $16.78 and a 200-day moving average price of $14.27. AngioDynamics Inc. has a one year low of $9.71 and a one year high of $17.64. The firm’s market capitalization is $599.87 million.
AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, October 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.04. The firm earned $88.10 million during the quarter, compared to analyst estimates of $86.06 million. AngioDynamics had a positive return on equity of 3.94% and a negative net margin of 12.57%. AngioDynamics’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business posted $0.11 earnings per share. On average, analysts predict that AngioDynamics Inc. will post $0.63 earnings per share for the current fiscal year.
In other AngioDynamics news, Director David F. Burgstahler sold 2,250,000 shares of AngioDynamics stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the completion of the sale, the director now directly owns 23,988 shares of the company’s stock, valued at approximately $350,704.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The disclosure for this sale can be found here. 1.88% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the company. Panagora Asset Management Inc. increased its stake in shares of AngioDynamics by 53.5% in the second quarter. Panagora Asset Management Inc. now owns 31,077 shares of the company’s stock worth $447,000 after buying an additional 10,833 shares during the period. Guggenheim Capital LLC increased its stake in shares of AngioDynamics by 2.5% in the second quarter. Guggenheim Capital LLC now owns 78,480 shares of the company’s stock worth $1,128,000 after buying an additional 1,910 shares during the period. Bridgeway Capital Management Inc. increased its stake in shares of AngioDynamics by 111.5% in the second quarter. Bridgeway Capital Management Inc. now owns 66,400 shares of the company’s stock worth $954,000 after buying an additional 35,000 shares during the period. C M Bidwell & Associates Ltd. acquired a new stake in shares of AngioDynamics during the second quarter worth about $109,000. Finally, Parametric Portfolio Associates LLC increased its stake in shares of AngioDynamics by 1.1% in the second quarter. Parametric Portfolio Associates LLC now owns 127,592 shares of the company’s stock worth $1,833,000 after buying an additional 1,436 shares during the period. 69.29% of the stock is owned by institutional investors.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.